Claim and evidence Close ×
Xu et al. (Nature Medicine, published online 3 June 2025) report a phase 2a randomized, placebo-controlled trial of rentosertib, which they describe as an AI-generated small-molecule inhibitor of a target discovered using generative AI. Copy claim link
Copy claim reference
Machine-checked, not reviewed by an editor Stated in source Supported
Supporting evidence: primary · 1 source
Date 2025-06-03 · publication Records dated 2025 → Role Articulation Register (kind of text) Nonfiction Scope of the passage A sponsor-authored trial report; the phase is as stated (2a). Scope and limits The record documents what this text states, in its register; it is not evidence that the proposition is true and implies no influence on or from any other text. Eleven authors are employees of Insilico Medicine, which the paper names as the study sponsor; the description of the molecule as AI-generated is the authors' own. The paper's description of its trial as "first" is the authors' wording and is not adopted here.
The evidence 02 primary source Supports the claim
A generative AI-discovered TNIK inhibitor for idiopathic pulmonary fibrosis: a randomized phase 2a trial ↗ Nature Medicine · 2025-06-03
Copy source reference
Cite the original source Cite the original document, not Selekoa. Check these details against it.
Copy APA
Download BibTeX Download RIS Download CSL-JSON
Source excerpt “a first-in-class AI-generated small-molecule inhibitor of TNIK, a first-in-class target in idiopathic pulmonary fibrosis (IPF) discovered using generative AI.” Location in source Abstract
How it was read Retrieved directly from the publisher
Machine-checked · 2026-10-30
Source details and check notes Authors Zuojun Xu; Feng Ren; Ping Wang; Alex Zhavoronkov Version Retrieved for the candidate pack on 2026-10-30 (SHA-256 ef9e787bc19076ee7fd0031e2edef34ff77b1f3796db7d7baa0e1ecefee66806). Nature Medicine article page, open access, version of record of 3 June 2025, as served on 2026-10-30. The author list is partial: it gives the authors the retrieved expression names and leaves out those it abbreviates. Canonical address Open the canonical source ↗ Accessed 2026-10-30 Language English (en) Attribution Zuojun Xu, Feng Ren, Ping Wang, Alex Zhavoronkov, “A generative AI-discovered TNIK inhibitor for idiopathic pulmonary fibrosis: a randomized phase 2a trial”, 2025-06-03. Reuse No open redistribution licence asserted. Bibliographic metadata, editorial paraphrases and short attributed quotations (at most 50 words each). Recheck terms before wider redistribution. Check notes Candidate pack passage, AI in biology (research/ai-in-biology). The quotation (19 words) matched the text retrieved for the candidate pack on 2026-10-30. Matching ignored differences of whitespace, case, quotation marks, dashes and Unicode compatibility forms, so the source’s typography can differ. How the authors describe the candidate. A cross-family machine check (2026-10-30, item B116) re-read the record’s sources and found full support. No human editorial review. primary source Supports the claim
A generative AI-discovered TNIK inhibitor for idiopathic pulmonary fibrosis: a randomized phase 2a trial ↗ Nature Medicine · 2025-06-03
Copy source reference
Cite the original source Cite the original document, not Selekoa. Check these details against it.
Copy APA
Download BibTeX Download RIS Download CSL-JSON
Source excerpt “are employees of Insilico Medicine. Insilico Medicine was the study sponsor.” Location in source Competing interests
How it was read Retrieved directly from the publisher
Machine-checked · 2026-10-30
Source details and check notes Authors Zuojun Xu; Feng Ren; Ping Wang; Alex Zhavoronkov Version Retrieved for the candidate pack on 2026-10-30 (SHA-256 ef9e787bc19076ee7fd0031e2edef34ff77b1f3796db7d7baa0e1ecefee66806). Nature Medicine article page, open access, version of record of 3 June 2025, as served on 2026-10-30. The author list is partial: it gives the authors the retrieved expression names and leaves out those it abbreviates. Canonical address Open the canonical source ↗ Accessed 2026-10-30 Language English (en) Attribution Zuojun Xu, Feng Ren, Ping Wang, Alex Zhavoronkov, “A generative AI-discovered TNIK inhibitor for idiopathic pulmonary fibrosis: a randomized phase 2a trial”, 2025-06-03. Reuse No open redistribution licence asserted. Bibliographic metadata, editorial paraphrases and short attributed quotations (at most 50 words each). Recheck terms before wider redistribution. Check notes Candidate pack passage, AI in biology (research/ai-in-biology). The quotation (11 words) matched the text retrieved for the candidate pack on 2026-10-30. Matching ignored differences of whitespace, case, quotation marks, dashes and Unicode compatibility forms, so the source’s typography can differ. The paper's own declaration, kept with the record. A cross-family machine check (2026-10-30, item B116) re-read the record’s sources and found full support. No human editorial review. Status and meaning Editorial status. Not reviewed by an editor . An exploratory record that no editor has accepted. This status does not say whether a person has read any linked passage. Each evidence record above shows how it was checked.
Relation. A passage of the document meets the proposition’s criterion. The record documents what the text states, in its register (fiction and satire are labelled); it is not evidence that the proposition is true and implies no influence on or from another text.
Date. Online publication date printed on the article page.
Record ID aib-arg-p3-xu-2025